A Study of Soticlestat in Healthy Adults To Evaluate the Effect on QTc Interval

NCT ID: NCT05309902

Last Updated: 2022-11-14

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-11
• Study Completion Date: 2022-12-06

Brief Summary

The main aim is to see if soticlestat has any effect in the heart rate.

Participants will receive 4 doses of soticlestat in tablets and will complete some assessment which include to record activity of the heart and collection of blood samples.

Then, the clinic will contact the participants 14 days after their final dose of soticlestat to check if they have any health problems.

Detailed Description

The drug being tested in this study is called soticlestat. Soticlestat is being tested in healthy participants for the purpose of this study. This study will assess the effect of single-dose of soticlestat on the heart rate (QTc prolongation). The study will enroll approximately 60 participants.

Participants will be randomly assigned (by chance, like flipping a coin) to 1 of the 4 treatments sequences.

• Sequence 1: (Regimen A+ Regimen B + Regimen C + Regimen D)
• Sequence 2: (Regimen B+ Regimen D + Regimen A + Regimen C)
• Sequence 3: (Regimen C+ Regimen A + Regimen D + Regimen B)
• Sequence 4: (Regimen D+ Regimen C + Regimen B + Regimen A)

All participants will receive all 4 treatment regimens. Treatment order will remain undisclosed to the participants and study doctor (unless there is an urgent medical need). This is a single-center trial. Participants will be followed up for up to 14 days after the last dose of study drug for a follow-up assessment. The overall time to participate in this study is approximately 63 days including screening period and follow-up period.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: QUADRUPLE

Study Groups

Sequence 1: (Regimen A + Regimen B + Regimen C + Regimen D)

Regimen A (soticlestat 300 milligram \[mg\] tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.

Group Type: EXPERIMENTAL

Soticlestat

Intervention Type: DRUG

Soticlestat tablet.

Placebo

Intervention Type: DRUG

Soticlestat placebo-matching tablet.

Moxifloxacin

Intervention Type: DRUG

Moxifloxacin over-encapsulated tablet.

Placebo

Intervention Type: DRUG

Moxifloxacin placebo-matching capsule.

Sequence 2: (Regimen B + Regimen D + Regimen A + Regimen C)

Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen C (soticlestat -matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 4.

Group Type: EXPERIMENTAL

Soticlestat

Intervention Type: DRUG

Soticlestat tablet.

Placebo

Intervention Type: DRUG

Soticlestat placebo-matching tablet.

Moxifloxacin

Intervention Type: DRUG

Moxifloxacin over-encapsulated tablet.

Placebo

Intervention Type: DRUG

Moxifloxacin placebo-matching capsule.

Sequence 3: (Regimen C + Regimen A + Regimen D + Regimen B)

Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.

Group Type: EXPERIMENTAL

Soticlestat

Intervention Type: DRUG

Soticlestat tablet.

Placebo

Intervention Type: DRUG

Soticlestat placebo-matching tablet.

Moxifloxacin

Intervention Type: DRUG

Moxifloxacin over-encapsulated tablet.

Placebo

Intervention Type: DRUG

Moxifloxacin placebo-matching capsule.

Sequence 4: (Regimen D + Regimen C + Regimen B + Regimen A)

Regimen D (soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 1, followed by at least 7 days washout period, followed by Regimen C (soticlestat placebo-matching tablets + moxifloxacin 400 mg over-encapsulated tablet), orally, in fasting condition once on Day 1 of Treatment Period 2, followed by at least 7 days washout period, followed by Regimen B (soticlestat 900 mg tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition, once on Day 1 of Treatment Period 3, followed by at least 7 days washout period, followed by Regimen A (soticlestat 300 mg tablets + soticlestat placebo-matching tablets + moxifloxacin placebo-matching capsule), orally, in fasting condition once on Day 1 of Treatment Period 4.

Group Type: EXPERIMENTAL

Soticlestat

Intervention Type: DRUG

Soticlestat tablet.

Placebo

Intervention Type: DRUG

Soticlestat placebo-matching tablet.

Moxifloxacin

Intervention Type: DRUG

Moxifloxacin over-encapsulated tablet.

Placebo

Intervention Type: DRUG

Moxifloxacin placebo-matching capsule.

Interventions

Soticlestat

Soticlestat tablet.

Intervention Type: DRUG

Placebo

Soticlestat placebo-matching tablet.

Intervention Type: DRUG

Moxifloxacin

Moxifloxacin over-encapsulated tablet.

Intervention Type: DRUG

Placebo

Moxifloxacin placebo-matching capsule.

Intervention Type: DRUG

Other Intervention Names

TAK-935

Eligibility Criteria

Inclusion Criteria

1. Male participants agree to comply with any applicable contraceptive requirements of the protocol.

2. Body mass index (BMI) greater than or equal to (>=)18.0 and <=32.0 kilogram per square meter (kg/m^2) at screening.

3. Continuous non-smoker who has not used nicotine-containing products for at least 90 days prior to the first dosing, based on participant self-reporting.

4. No clinically significant history or presence of ECG findings as judged by the Investigator or designee, including each criterion as listed below:

• Normal sinus rhythm (HR between 45 bpm and 100 bpm inclusive) at screening and check-in;
• QTcF is <=450 ms (males) or <=470 ms (females) at screening and check-in;
• QRS interval <=110 ms; if >110 ms, result will be confirmed by a manual over read at screening and check-in;
• PR interval <=220 ms at screening and check-in.

Exclusion Criteria

1. Mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.

2. History or presence of any of the following, deemed clinically significant by the Investigator or designee:

• epilepsy, seizure, or convulsion, tremor or related symptoms;
• risk factors for Torsade de Pointes (TdP) (example, heart failure, unexplained syncope, cardiomyopathy, or family history of Long QT Syndrome);
• family history of sudden death;
• sick sinus syndrome, second or third degree atrioventricular block, myocardial infarction, pulmonary congestion, symptomatic or significant cardiac arrhythmia, prolonged QTcF interval, or conduction abnormalities;
• ischemic heart disease, poorly controlled hypertension, or other cardiovascular disorder;
• T wave flattening or other abnormalities which in the opinion of the investigator or designee may interfere with the analysis of QT intervals;
• clinically significant hyper- or hypokalemia.

3. Any positive responses on the Columbia-Suicide Severity Rating Scale (C-SSRS) that in the clinical judgement of the Investigator has a risk of suicide or has made a suicide attempt in the previous 12 months prior to the first dosing.

4. Positive urine drug or alcohol results at screening or at check-in.

5. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or antibody test for hepatitis C virus (HCV).

6. Unable to refrain from or anticipates the use of:

• Any vaccines, drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing. Thyroid hormone replacement medication may be permitted if the participant has been on the same stable dose for the immediate 3 months prior to first dosing.
• Any drugs known to be significant inducers of cytochrome P450 (CYP)3A, CYP2C19, uridine 5' diphospho-glucuronosyltransferase (UGT)1A9 or (UGT)2B4 enzymes and/or P-glycoprotein (P-gp), including St. John's Wort, within 28 days prior to the first dosing. Appropriate sources (example, Flockhart TableTM) will be consulted to confirm lack of Pharmacokinetics (PK)/pharmacodynamics interaction with study drug.

7. Consumes excessive amounts, defined as greater than 4 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks or other caffeinated beverages per day.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

Takeda

Related Links

https://clinicaltrials.takeda.com/study-detail/2089cfe856aa4315?idFilter=%5B%22TAK-935-1001%22%5D

To obtain more information on the study, click here/on this link

Other Identifiers

TAK-935-1001

Identifier Type: -

Identifier Source: org_study_id